Ad hoc announcement pursuant to Art. 53 LR February 21, 2025 Annual report of BB Biotech AG as at December 31, 2024  BB Biotech AG publishes its 2024 annual report BB Biotech AG published its annual report for fiscal year 2024 today. Besides the audited consolidated financial statements, the annual report contains detailed information on the bi [ … ]

Media release as at February 21, 2025 Annual Report 2024: BB Biotech positions for structural sector recovery amid shifting market dynamics 2024, especially the fourth quarter, signaled the early stage of a structural recovery in biotech, driven by renewed investor focus on clinical data, regulatory approvals, and commercial execution. BB Biotec [ … ]

Media release as of January 24, 2025 BB Biotech: Preliminary full-year 2024 results and dividend proposal BB Biotech AG reports the following preliminary and unaudited figures for 2024: Full-year 2024: BB Biotech shares delivered a total return of -13.5% in CHF and -14.1% in EUR (including the CHF 2.00 dividend paid in March 2024). NAV performan [ … ]

Ad hoc announcement pursuant to Art. 53 LR January 24, 2025 BB Biotech AG closes the 2024 fiscal year with a profit In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information: Based on its preliminary unaudited consolidated figures, BB Biotech AG reports a profit of approximately [ … ]

  London, UK, 22 January 2025   Edison issues report on BB Biotech (BION) Edison issues report on BB Biotech (BION). BB Biotech (BION) is the largest biotech investor among its investment company peers. The company is focused on achieving long-term capital growth by investing in high-quality biotech assets developing and marketing innovative d [ … ]